{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:23:02Z","timestamp":1765732982312,"version":"3.48.0"},"reference-count":48,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016309","name":"Bayer, United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016309","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,10,22]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to determine the clinical utility of the androgen deprivation therapy (ADT)+docetaxel (DOCE)+androgen receptor-targeted agent (ARTA) triplet therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A modified Delphi method. A steering group of eight UK healthcare professionals experienced in prostate cancer care discussed treatment challenges, developing 39 consensus statements across four topics. Agreement with the statements was tested with a broader panel of professionals within this therapeutic area in the UK through an anonymous survey, using a four-point Likert scale. This was distributed by the steering group members and an independent third party. Following the survey, the steering group convened to discuss the results and formulate recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The steering group convened online for discussions. The survey was distributed via email by the clinicians and the independent third party.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Healthcare professionals involved in the provision of prostate cancer care, working in relevant professional roles (oncology, urology or geriatric consultant, oncology nurse specialist, and hospital pharmacist) within the UK. No patients or members of the public were involved within the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Consensus was defined as high (\u226575% agreement) and very high (\u226590% agreement).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Responses were received from 120 healthcare professionals, including oncologists (n=73), urologists (n=16), geriatricians (n=15), nurse specialists (n=11) and hospital pharmacists (n=5). Consensus was reached for 37 out of 39 (95%) statements, and 27\/39 (69%) statements achieved very high agreement \u226590%. Consensus was not reached for 2\/39 (5%) statements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the consensus observed, the steering group developed a set of recommendations for the clinical utility of ADT+DOCE+ARTA in treating patients with mHSPC in the UK. Following these recommendations enables clinicians to identify appropriate patients with mHSPC for triplet treatment, thereby improving patients\u2019 outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-090013","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:32:16Z","timestamp":1732768336000},"page":"e090013","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["A modified Delphi consensus regarding the clinical utility of triplet therapy in patients with metastatic hormone-sensitive prostate cancer patients in the UK"],"prefix":"10.1136","volume":"14","author":[{"given":"Hilary","family":"Glen","sequence":"first","affiliation":[{"name":"Beatson West of Scotland Cancer Centre, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bahl","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol NHS Foundation Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Fleure","sequence":"additional","affiliation":[{"name":"Guy's and Saint Thomas' NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Clarke","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK"},{"name":"The Christie NHS Foundation Trust, Manchester, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneil","family":"Jain","sequence":"additional","affiliation":[{"name":"Queen's University Belfast, Belfast, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Kalsi","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas' NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Khoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junaid","family":"Mobeen","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2025121409185284000_14.11.e090013.1","unstructured":"Cancer Research UK . Prostate cancer statistics, 2024. Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer"},{"key":"2025121409185284000_14.11.e090013.2","unstructured":"National Prostate Cancer Audit . NPCA State of the Nation Report - An audit of the care received by people with prostate cancer in England and Wales from 01\/01\/2019 to 31\/01\/2023. 2024."},{"key":"2025121409185284000_14.11.e090013.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204945","article-title":"De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?","volume":"15","author":"Piombino","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025121409185284000_14.11.e090013.4","doi-asserted-by":"crossref","unstructured":"Hamid AA , Sayegh N , Tombal B , et al . Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. Am Soc Clin Oncol Educ Book 2023. doi:10.1200\/EDBK_390166","DOI":"10.1200\/EDBK_390166"},{"key":"2025121409185284000_14.11.e090013.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101194","article-title":"Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy","volume":"8","author":"Oing","year":"2023","journal-title":"ESMO Open"},{"key":"2025121409185284000_14.11.e090013.6","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025121409185284000_14.11.e090013.7","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.3390\/curroncol29070362","article-title":"Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy","volume":"29","author":"Verzoni","year":"2022","journal-title":"Curr Oncol"},{"key":"2025121409185284000_14.11.e090013.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011"},{"key":"2025121409185284000_14.11.e090013.9","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"2025121409185284000_14.11.e090013.10","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.7533"},{"key":"2025121409185284000_14.11.e090013.11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/rg.2020190121","article-title":"Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review","volume":"40","author":"Tanaka","year":"2020","journal-title":"Radiographics"},{"key":"2025121409185284000_14.11.e090013.12","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2020.1159","article-title":"A pictorial review of the less commonly encountered patterns of metastatic prostate carcinoma","volume":"14","author":"Gosein","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"2025121409185284000_14.11.e090013.13","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11070664","article-title":"Tissue- and Liquid-Based Biomarkers in Prostate Cancer Precision Medicine","volume":"11","author":"Meehan","year":"2021","journal-title":"J Pers Med"},{"key":"2025121409185284000_14.11.e090013.14","doi-asserted-by":"publisher","DOI":"10.21873\/cgp.20359"},{"key":"2025121409185284000_14.11.e090013.15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s43094-023-00573-2","article-title":"Unlocking the power of precision medicine: exploring the role of biomarkers in cancer management","volume":"10","author":"Gadade","year":"2024","journal-title":"Futur J Pharm Sci"},{"key":"2025121409185284000_14.11.e090013.16","first-page":"120","article-title":"Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer?","volume":"18","author":"Hack","year":"2022","journal-title":"Oncol & Haematol"},{"key":"2025121409185284000_14.11.e090013.17","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025121409185284000_14.11.e090013.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.955925","article-title":"Systemic triplet therapy for metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis","volume":"13","author":"Jian","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025121409185284000_14.11.e090013.19","unstructured":"Mottet N , Cornford P , Bergh R , et al . EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer, 2023. Available: https:\/\/uroweb.org\/guidelines\/prostate-cancer"},{"key":"2025121409185284000_14.11.e090013.20","article-title":"A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?","volume":"42","author":"Shore","year":"2024","journal-title":"J C O"},{"key":"2025121409185284000_14.11.e090013.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"2025121409185284000_14.11.e090013.22","doi-asserted-by":"crossref","unstructured":"Chi KN , Chowdhury S , Bjartell A , et al . [Phase III TITAN Study] Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, 2021.","DOI":"10.1200\/JCO.20.03488"},{"key":"2025121409185284000_14.11.e090013.23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025121409185284000_14.11.e090013.24","unstructured":"National Institute for Health and Care Excellence . Prostate cancer: diagnosis and management (ng131). 2021."},{"key":"2025121409185284000_14.11.e090013.25","unstructured":"National Institute for Health and Care Excellence . Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer. 2023."},{"key":"2025121409185284000_14.11.e090013.26","unstructured":"NHS England . Clinical Commissioning Policy Statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone na\u00efve metastatic prostate cancer [B15\/PS\/a]. 2016."},{"key":"2025121409185284000_14.11.e090013.27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MOU.0000000000001124","article-title":"Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions","volume":"33","author":"Zattoni","year":"2023","journal-title":"Curr Opin Urol"},{"key":"2025121409185284000_14.11.e090013.28","article-title":"Use of Delphi in health sciences research: A narrative review","volume":"102","author":"Shang","year":"2023","journal-title":"Medicine (Abingdon)"},{"key":"2025121409185284000_14.11.e090013.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1601827113"},{"key":"2025121409185284000_14.11.e090013.30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1193147"},{"key":"2025121409185284000_14.11.e090013.31","doi-asserted-by":"publisher","DOI":"10.1177\/0269216317690685"},{"key":"2025121409185284000_14.11.e090013.32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (ACcurate COnsensus Reporting Document): A reporting guideline for consensus methods in biomedicine developed via a modified Delphi","volume":"21","author":"Gattrell","year":"2024","journal-title":"PLoS Med"},{"key":"2025121409185284000_14.11.e090013.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"2025121409185284000_14.11.e090013.34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"2025121409185284000_14.11.e090013.35","unstructured":"National Institute for Health and Care Excellence . Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (ta721). 2021."},{"key":"2025121409185284000_14.11.e090013.36","unstructured":"National Prostate Cancer Audit . Annual Report 2022 - Prostate Cancer services during the COVID-19 Pandemic. 2022."},{"key":"2025121409185284000_14.11.e090013.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2740","article-title":"1790P Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK","volume":"34","author":"Dodkins","year":"2023","journal-title":"Ann Oncol"},{"key":"2025121409185284000_14.11.e090013.38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial","volume":"40","author":"Rush","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025121409185284000_14.11.e090013.39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41391-023-00668-0","article-title":"Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy","volume":"27","author":"Afferi","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025121409185284000_14.11.e090013.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"2025121409185284000_14.11.e090013.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"2025121409185284000_14.11.e090013.42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2025121409185284000_14.11.e090013.43","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-023-01009-x","article-title":"Impact of non-regional lymph node metastases accurately revealed on 18F-PSMA-1007 PET\/CT in the clinical management of metastatic hormone-sensitive prostate cancer","volume":"13","author":"Jiang","year":"2023","journal-title":"EJNMMI Res"},{"key":"2025121409185284000_14.11.e090013.44","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1055\/s-0041-1730035","article-title":"Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life","volume":"5","author":"Zappulla","year":"2021","journal-title":"TH Open"},{"key":"2025121409185284000_14.11.e090013.45","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2021.02.031","article-title":"Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis","volume":"80","author":"Glicksman","year":"2021","journal-title":"Eur Urol"},{"key":"2025121409185284000_14.11.e090013.46","doi-asserted-by":"crossref","unstructured":"Alessy SA , Davies E , Rawlinson J , et al . Clinical nurse specialists and survival in patients with cancer: the UK National Cancer Experience Survey. BMJ Supp Palliat Care 2022.:bmjspcare-2021-003445. doi:10.1136\/bmjspcare-2021-003445","DOI":"10.1136\/bmjspcare-2021-003445"},{"key":"2025121409185284000_14.11.e090013.47","doi-asserted-by":"crossref","unstructured":"Kerr H , Donovan M , McSorley O . Evaluation of the role of the clinical Nurse Specialist in cancer care: an integrative literature review. Eur J Cancer Care 2021;30. doi:10.1111\/ecc.13415","DOI":"10.1111\/ecc.13415"},{"key":"2025121409185284000_14.11.e090013.48","unstructured":"Macmillan Cancer Support . Addressing the gap - Highlighting the need for growing the specialist cancer nursing workforce. 2020."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-090013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:19:03Z","timestamp":1765732743000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-090013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,27]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/bmjopen-2024-090013"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-090013","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}